Left Ventricular Hypertrophy in New Hemodialysis Patients without Symptomatic Cardiac Disease
Open Access
- 1 May 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 5 (5), 805-813
- https://doi.org/10.2215/cjn.07761109
Abstract
Background and objectives: Although left ventricular hypertrophy (LVH) is a characteristic finding in hemodialysis (HD) populations, few risk factors for progressive LVH have been identified. Design, setting, participants, & measurements: As part of a multinational, blinded, randomized, controlled trial that demonstrated no effect of hemoglobin targets on LV size, 596 incident HD patients, without symptomatic cardiac disease or cardiac dilation, had baseline echocardiograms within 18 months of starting dialysis and subsequently at 24, 48, and 96 weeks later. A wide array of baseline risk factors were assessed, as were BP and hemoglobin levels during the trial. Results: The median age and duration of dialysis were 51.5 years and 9 months, respectively. LV mass index (LVMI) rose substantially during follow-up (114.2 g/m2 at baseline, 121 at week 48, 123.4 at week 48, and 128.3 at week 96), as did fractional shortening, whereas LV volume (68.7, 70.1, 68.7, and 68.1 ml/m2) and E/A ratio remained unchanged. At baseline, the only multivariate associations of LVMI were gender and N terminal pro–B type natriuretic peptide. Comparing first and last echocardiograms in those without LVH at baseline, independent predictors of increase in LVMI were higher time-integrated systolic BP and cause of ESRD. An unadjusted association between baseline LVMI and subsequent cardiovascular events or death was eliminated by adjusting for age, diabetes, systolic BP, and N terminal pro–B type natriuretic peptide. Conclusions: Progressive concentric LVH and hyperkinesis occur in HD patients, which is partly explained by hypertension but not by a wide array of potential risk factors, including anemia.Keywords
This publication has 24 references indexed in Scilit:
- Erythropoietin Therapy and Left Ventricular Mass Index in CKD and ESRD PatientsClinical Journal of the American Society of Nephrology, 2009
- Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressureKidney International, 2009
- Left ventricular hypertrophy in renal disease: beyond preload and afterloadKidney International, 2009
- The association of sudden cardiac death with inflammation and other traditional risk factorsKidney International, 2008
- Outcome and risk factors for left ventricular disorders in chronic uraemiaNephrology Dialysis Transplantation, 1996
- Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal diseaseKidney International, 1996
- Clinical and echocardiographic disease in patients starting end-stage renal disease therapyKidney International, 1995
- Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods.Hypertension, 1987
- Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.Circulation, 1978
- Left Ventricular Volumes and Ejection Fraction by EchocardiographyCirculation, 1971